Literature DB >> 11071396

Role of prolactin in chloro-S-triazine rat mammary tumorigenesis.

J C O'Connor1, D R Plowchalk, C S Van Pelt, L G Davis, J C Cook.   

Abstract

Chloro-S-triazine herbicides [cyanazine (CZ), atrazine (AZ), simazine (SZ)] increase mammary tumors in Crl:CD BR rats but not in F-344 rats or in mice. A nongenotoxic mechanism was investigated since the chloro-S-triazines are negative in short-term tests for genotoxicity. An in vivo battery was used to assess the chloro-S-triazines for estrogenic activity or for their ability to increase prolactin (PRL) levels, both of which play important roles in enhancing mammary gland tumorigenesis in rodents. Ovariectomized (OVX) female rats were treated with AZ, CZ, SZ, or three CZ metabolites for 4 days via intraperitoneal injection. The pattern of responses between the chloro-S-triazines and four controls (estradiol, estriol, haloperidol, reserpine) was compared. For the 6 end-points examined, the responses from rats treated with AZ, CZ, SZ, and the metabolites of CZ most closely matched the responses from the reserpine-treated rats (a PRL rather than estrogenic mechanism). In addition, AZ, CZ, and SZ were tested in several other in vitro models (estrogen/biogenic amine receptor competition assays and a yeast-expressed human estrogen receptor transcription assay) as well as an in vivo 24 h time-course experiment to characterize the CZ-induced increases in PRL levels. AZ, CZ, and SZ are not estrogen receptor (ER) activating compounds based on yeast transactivation and receptor competition data. CZ and AZ demonstrated marginal competition (at mM levels) to the D and alpha2 adrenergic receptors. Ligands to the D2 receptor, but not the alpha2 adrenergic receptor, are known to induce mammary tumors. CZ was also found to produce elevated PRL levels in a time-course similar to that seen with reserpine and haloperidol. Overall, the pattern of responses obtained with the chloro-S-triazines most closely matched the responses observed for reserpine. Taken together, these data suggest chloro-S-triazine-induced mammary tumors in rats are mediated through a PRL mechanism, which is thought to be of low relevance to humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11071396     DOI: 10.1081/dct-100101972

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  6 in total

1.  Atrazine acts as an endocrine disrupter by inhibiting cAMP-specific phosphodiesterase-4.

Authors:  Marek Kucka; Kristina Pogrmic-Majkic; Svetlana Fa; Stanko S Stojilkovic; Radmila Kovacevic
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-27       Impact factor: 4.219

Review 2.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

3.  Atrazine binds to the growth hormone-releasing hormone receptor and affects growth hormone gene expression.

Authors:  Walid D Fakhouri; Joseph L Nuñez; Frances Trail
Journal:  Environ Health Perspect       Date:  2010-06-08       Impact factor: 9.031

4.  Atrazine and breast cancer: a framework assessment of the toxicological and epidemiological evidence.

Authors:  James W Simpkins; James A Swenberg; Noel Weiss; David Brusick; J Charles Eldridge; James T Stevens; Robert J Handa; Russell C Hovey; Tony M Plant; Timothy P Pastoor; Charles B Breckenridge
Journal:  Toxicol Sci       Date:  2011-07-18       Impact factor: 4.849

5.  Low prevalence of anti-xenobiotic antibodies among the occupationally exposed individuals is associated with a high risk of cancer.

Authors:  Mohammad Sajid; Javed N Agrewala
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

6.  Assessing exposure to atrazine and its metabolites using biomonitoring.

Authors:  Dana B Barr; Parinya Panuwet; Johnny V Nguyen; Simeon Udunka; Larry L Needham
Journal:  Environ Health Perspect       Date:  2007-10       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.